Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00369434 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women
A Phase 3 study of Menopause and Vasomotor System, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT00369434: Completed Phase 3 study of Menopause and Vasomotor System, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00369434 is a Phase 3 study of Menopause and Vasomotor System that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 450 participants, below the 9,386-participant average among 54 other Menopause trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00369434, a Phase 3 study of Menopause and Vasomotor System, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS SR, an extended release form of desvenlafaxine succinate, in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) associated with menopause in a population of postmenopausal women.
Conditions Studied
Interventions
- DRUG Desvenlafaxine succinate sustained-release (DVS SR)
Study Locations (20)
Florida
- - Brooksville
- - Inverness
- - Miami
- - New Port Richey
- - Ocala
- - St. Petersburg
- - Tampa
Georgia
- - Decatur
- - Savannah
Idaho
- - Boise
- - Idaho Falls
Alabama
- - Montgomery
Arizona
- - Peoria
California
- - Upland
Colorado
- - Colorado Springs
Kansas
- - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-02 |
| Phase | Phase 3 |
What the finished NCT00369434 record still lists
NCT00369434 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, below the 9,386-participant average among 54 other Menopause trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Menopause appearing as the primary indexed condition, and to 1 intervention - of which Desvenlafaxine succinate sustained-release (DVS SR) is the first listed.
NCT00369434 names 20 study sites across 12 states, led by Florida, Georgia, Idaho.
Frequently Asked Questions
What is clinical trial NCT00369434 about?
NCT00369434 is a clinical study titled "Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women". The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS SR, an extended release form of desvenlafaxine succinate, in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) associated with menopause in a population of postmenopausal women.
What is the current status of trial NCT00369434?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2006-06. Estimated completion is 2007-02.
What conditions does trial NCT00369434 study?
This clinical trial studies the following conditions: Menopause, Vasomotor System.
What interventions are being tested in trial NCT00369434?
The interventions under investigation include: Desvenlafaxine succinate sustained-release (DVS SR) (DRUG).
Who is sponsoring clinical trial NCT00369434?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00369434 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menopause
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00369434's enrollment target sits among peer trials
450 4th of 54 higher than 51 of 54 other Menopause trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Menopause trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms
COMPLETED · Phase 3
-
Therapy to Prevent Sexual Pain in Breast Cancer Survivors
COMPLETED · Phase 3
-
Menopause Transition, Sex Hormone Deficiency and Autonomic and Vascular Function
RECRUITING
-
Autonomic Regulation of Blood Pressure in Premature and Early Menopausal Women
RECRUITING
-
Apple Women's Health Study
RECRUITING
-
Hot Flashes and Neurovascular Function in Women
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia